Wealthfront’s Teva Pharmaceuticals TEVA Stock Holding History

Wealthfront’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-167	Closed	-$9K	–	967
2015 Q3	$9K	Buy	+167	New	+$10.8K	﹤0.01%	993

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Wealthfront's TEVA Position: Q4 2015 in Review

Wealthfront sold out of Teva Pharmaceuticals (TEVA) in Q4 2015, closing a stake of 167 shares — an estimated $9K sold.

Wealthfront first reported a position in TEVA in Q3 2015 and held it in 1 quarter. The position peaked at $9K in Q3 2015. 876 funds tracked by Wall St. Rank hold TEVA as of Q4 2015.

Wealthfront reported no remaining Teva Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Wealthfront sold 167 Teva Pharmaceuticals shares in Q4 2015, an estimated $9K.
Wealthfront first reported a position in Teva Pharmaceuticals in Q3 2015 and held it in 1 quarter.
Wealthfront's Teva Pharmaceuticals position peaked at $9K in Q3 2015.
876 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2015.

Based on Wealthfront's 13F filing for Q4 2015, filed 17 Feb 2016.